IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)

Last updated: June 25, 2025
Sponsor: Imbria Pharmaceuticals, Inc.
Overall Status: Completed

Phase

2

Condition

Diabetes And Hypertension

Circulation Disorders

Diabetes Mellitus, Type 2

Treatment

IMB-1018972

Clinical Study ID

NCT04826159
IMB101-005
  • Ages 18-80
  • All Genders

Study Summary

The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of type 2 diabetes

  • Elevated HbA1c

  • Elevated BMI

  • Preserved left ventricular ejection fraction

  • Diagnosis of HFpEF (Stage 2 only)

Exclusion

Exclusion Criteria:

  • Uncontrolled hypertension

  • Contraindication to magnetic resonance scanning

  • More than mild to moderate valvular heart disease

  • Atrial fibrillation

  • History of sustained ventricular tachycardia or cardiac arrest

  • Inability to exercise (Stage 2 only)

  • Clinically significant concurrent condition which could prevent the patient fromperforming any of the protocol-specified assessments, represent a safety concern ifthe patient participates in the trial or could confound trial assessments of safetyor tolerability

Study Design

Total Participants: 49
Treatment Group(s): 1
Primary Treatment: IMB-1018972
Phase: 2
Study Start date:
April 21, 2021
Estimated Completion Date:
August 06, 2024

Connect with a study center

  • Oxford University Hospital

    Oxford, OX3 9DU
    United Kingdom

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.